HPV “Coverage”
2015; Massachusetts Medical Society; Volume: 372; Issue: 8 Linguagem: Inglês
10.1056/nejme1415742
ISSN1533-4406
Autores Tópico(s)Colorectal and Anal Carcinomas
ResumoThis issue of the Journal presents a milestone in expanding the coverage of cancers associated with the human papillomavirus (HPV). Joura and colleagues1 report the results of a randomized, controlled trial of a new 9-valent HPV vaccine versus a quadrivalent HPV vaccine in more than 14,000 young women. The authors found that the new vaccine had an efficacy of nearly 97% against high-grade cervical, vulvar, and vaginal disease related to HPV types 31, 33, 45, 52, and 58. In the intention-to-treat analysis, the 9-valent vaccine was not found to be more beneficial than the quadrivalent vaccine, presumably because so many . . .
Referência(s)